SCHEMBL5783453

SCHEMBL5783453

COc1ccc2c(c1)c(S(=O)(=O)c1ccccc1)nn2CCN1CCCC1

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 13/20 0.56
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
HSD17B10 Q99714 1/20 0.45
HPGD P15428 2/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
RCE1 Q9Y256 1/20 0.44
MAPT P10636 2/20 0.41
LMNA P02545 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
BCHE P06276 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5784573 0.94 HTR6 (0.54) HTR6ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL5786145 0.86 HTR6 (0.50) HTR6L3MBTL1
SCHEMBL5785300 0.84 HTR6 (0.48) HTR6L3MBTL1
SCHEMBL5783466 0.82 CNR2 (0.48) HTR6ALDH1A1KDM4EL3MBTL1BCHE
SCHEMBL5784603 0.77 HTR6 (0.60) HTR6ALDH1A1KDM4EHSD17B10MAPT
SCHEMBL5784035 0.75 HTR6 (0.47) HTR6BCHECNR1CNR2
SCHEMBL5782703 0.74 HTR6 (0.58) HTR6MAPT
SCHEMBL5783884 0.74 HTR6 (0.42) HTR6MAPTLMNAHTT
SCHEMBL5784091 0.72 HTR6 (0.43) HTR6LMNAHTT
SCHEMBL5499055 0.72 HTR6 (1.00) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1509501-B1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH CORP (US) 2006-12-20 EP claimed
US-6727246-B2 ENHANCEMENT OF COGNITION AND MEMORY IN HUMAN DISEASES SUCH AS ALZHEIMER'S WYETH 2004-04-27 US claimed
US-20030232828-A1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND-INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH 2003-12-18 US claimed
EP-1509501-B1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND -INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH CORP (US) 2006-12-20 EP disclosed
US-6727246-B2 ENHANCEMENT OF COGNITION AND MEMORY IN HUMAN DISEASES SUCH AS ALZHEIMER'S WYETH 2004-04-27 US disclosed
US-20030232828-A1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND-INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232828-A1 1-(AMINOALKYL)-3-SULFONYLINDOLE AND-INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS HTR6, HTR3A, HTR5A HTR6 1/4885ALDH1A1 633/4885KDM4E 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.